Inuxair

Formoterol fumarate dihydrate and beclometasone dipropionate anhydrous, the active ingredient in Inuxair, is an inhaled corticosteroid/long‑acting β2‑agonist combination presented as an inhalation aerosol for inhalation use. It is indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults.

GNH USA supplies Inuxair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable supply chains, on‑time delivery, and dedicated technical support throughout the procurement process.

Inuxair is used as a maintenance inhaler that targets airway inflammation and bronchoconstriction in respiratory disease.

Asthma: improves symptom control and reduces exacerbations. COPD: enhances lung function and decreases breathlessness. Chronic bronchitis (a component of COPD): reduces airway inflammation and frequency of flare‑ups.

Inuxair may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Throat irritation or soreness - Cough - Hoarseness or voice change - Oral candidiasis (thrush) - Headache - Tremor

Serious or Rare Side Effects: - Paradoxical bronchospasm - Severe allergic reaction (anaphylaxis) - Pneumonia - Cardiac arrhythmia or tachycardia - Hyperglycemia - Adrenal suppression

Before prescribing Inuxair, clinicians should evaluate patient history and follow safety guidelines.

Assess for active infections: avoid use during untreated bacterial, viral or fungal respiratory infections. Monitor for tuberculosis: screen patients with risk factors before initiating therapy. Use lowest effective dose: titrate to control symptoms while minimizing exposure. Avoid abrupt discontinuation: taper under medical supervision to prevent loss of control. Educate on inhaler technique: ensure proper mouth rinsing after use to reduce oral candidiasis. Store at ambient temperature below 25°C: keep in original container, protect from moisture and direct sunlight.

Inuxair can interact with other medicines that affect the respiratory or cardiovascular systems.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants: increase risk of cardiovascular side effects from formoterol. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): raise systemic exposure to formoterol, raising risk of tachycardia.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypokalemia caused by β2‑agonists. - Theophylline: additive stimulatory effect on the heart may increase arrhythmia risk. - Other inhaled corticosteroids: cumulative steroid load may increase risk of systemic effects.